ALT logo

ALTIMMUNE INC

ALTNASDAQ
🏆 #3009 by market capEarnings Nov 10 · PreUS Equity
$2.13▲ $0.03 (+1.67%)
Pre-market · at close
🔔
Track ALT
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.7%
7d▲ 0.9%
14d▼ 3.0%
30d▼ 25.5%
ytd▼ 40.9%
1y▼ 47.5%
🏦Market Cap
$414M
Small Cap
📈Revenue Growth (YoY)
55.0%
High Growth
📊Gross Margin
—
💵FCF Margin
439.0%
Strong
⚖️P/S Ratio
10200.3x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$2.10 – $2.17
52-Week Range
$2.00 – $6.44
Volume (shares)
115,279
Avg Volume (shares)
—
Shares Outstanding
194.5M
Next Earnings
2026-11-10

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
10200.3x
EPS (TTM)
$-0.78
Dividend Yield
—
Dilution (1yr)
+41.2%
ALT logo

ALTIMMUNE INC

ALT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$41K▲ +105.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$94M▼ −8.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$68M▼ −15.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
100.6M▲ +41.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8M▼ −$27M YoY
StockOtter · stockotter.space

About ALTIMMUNE INC

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
15 analysts
Strong Buy4
Buy9
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.